Drugs / AZD2115
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03097380 | Apr → Dec 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01445782 | Oct 2011 → Jul 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01283984 | Jan → Aug 2011 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02109406 | May → Sep 2014 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01498081 | Mar → Oct 2012 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03097380 ↗ |
| Route | Inhaled | “oral inhalation” NCT01283984 ↗ |